Rezolute reports Phase 3 sunRIZE CGM data showing improved hypoglycemia control with ersodetug

• Rezolute reported expanded Phase 3 sunRIZE analyses for ersodetug in congenital hyperinsulinism, already presented at Pediatric Endocrine Society 2026 Annual Meeting.
• Additional continuous glucose monitoring readouts showed broadly consistent improvements in glycemic control for ersodetug versus placebo, despite missing statistical significance on a key secondary endpoint at Week 24.
• Open-label extension follow-up indicated sustained benefit, supporting reduction or discontinuation of background standard-of-care therapies in many patients.
• FDA Type B meeting on March 17, 2026 led agency to request submission of broader study dataset to inform next steps toward a potential approval path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605011215PRIMZONEFULLFEED9711532) on May 01, 2026, and is solely responsible for the information contained therein.